CTOs on the Move

Ohana Biosciences

www.ohanabio.com

 
Ohana is pioneering a new frontier in reproductive medicine. Built upon a world-leading understanding of sperm biology, Ohana has created a best-in-class proprietary platform with broad applications across reproductive medicine.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ohanabio.com
  • 325, Vassar Street
    Cambridge, MA USA 02139
  • Phone: 617.674.9200

Executives

Name Title Contact Details
Nathan McBride
Vice President, Information Technology Profile

Similar Companies

Virobay

Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis.  The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.

Haematologic Technologies

A large molecule CRO combining world-class protein chemistry expertise, integrated large molecule analytical services, and coagulation reagents for biopharma R&D.

Abbott Diabetes Care

Abbott Diabetes Care is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmaceutical Product Development

The Pharmaceutical Product Development, LLC is a global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services.

Obsidian Therapeutics

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian`s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients. Our aspirations are high, and we`re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need. Located in the heart of Cambridge, we`re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.